Mitochondrial regulation of cellular senescence heterogeneity

Cellular senescence is a stable cell-cycle arrest program accompanied by extensive metabolic remodeling and acquisition of a senescence-associated secretory phenotype (SASP). Emerging evidence indicates that senescence is not a uniform endpoint but a heterogeneous spectrum of cell states shaped by the nature of the initiating stimulus. Mitochondria have recently emerged as central regulators of this heterogeneity by integrating metabolic, redox, and inflammatory signaling. Senescent cells share common mitochondrial features-including increased mitochondrial mass, elevated reactive oxygen species (ROS), impaired mitophagy, and altered metabolic programs-yet distinct senescence subtypes exhibit unique mitochondrial adaptations. Replicative senescence is governed by a telomere–mitochondria feedback loop, whereas stress- and oncogene-induced senescence involve rapid mitochondrial stress responses and stimulus-specific metabolic rewiring. Therapy-induced senescence further introduces context-dependent mitochondrial dependencies that influence therapeutic resistance and senolytic vulnerability. Mitochondrial dysfunction actively drives senescence heterogeneity by modulating cellular metabolism, influencing cell fate decisions, and regulating the expression of key senescence-associated genes. The integration of mitochondrial signaling pathways with other cellular processes underscores the complex interplay between mitochondria and senescence. Understanding this relationship is crucial for developing targeted therapeutic strategies that selectively modulate or eliminate senescent cells. Research using RUO laboratory peptides can provide valuable insights into the molecular mechanisms underlying senescence heterogeneity, enabling the development of precision interventions in aging and cancer.